Lan Fang
Impact in
- Immunology top 10%
- interferon and immune responses
- Immune cells in cancer
- Phagocytosis and Immune Regulation
- IL-33, ST2, and ILC Pathways
- Immune Cell Function and Interaction
Papers in
-
- Epigenetics and DNA Methylation 3
- Ubiquitin and proteasome pathways 2
- Cancer-related gene regulation 2
- Inflammasome and immune disorders 2
- Immunology 10
- interferon and immune responses 3
- IL-33, ST2, and ILC Pathways 2
- Co-authors
- Linjun Weng (3 shared papers)Yufeng Shi (3 shared papers)Yue Liu (3 shared papers)Qi Wu (2 shared papers)Pengcheng Zhao (2 shared papers)Yanjin Wang (2 shared papers)Jin Zhang (2 shared papers)Yanrong Yang (1 shared paper)
- Journals
- Advanced Science (2 papers)Cancer Biology and Medicine (2 papers)Developmental Cell (1 paper)Signal Transduction and Targeted Therapy (1 paper)Journal of Hematology & Oncology (1 paper)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Lan Fang
18 papers receiving 847 citations
Lan Fang's Hit Papers
Peers
Comparison fields: 5 of 79
- Immunology 333
- Cancer Research 92
- Oncology 161
- Molecular Biology 378
- Biomaterials 46
Countries citing papers authored by Lan Fang
This map shows the geographic impact of Lan Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lan Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lan Fang more than expected).
Fields of papers citing papers by Lan Fang
This network shows the impact of papers produced by Lan Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lan Fang. The network helps show where Lan Fang may publish in the future.
Co-authors
The 25 scholars most cited alongside Lan Fang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Emerging phagocytosis checkpoints in cancer immunotherapy Hit paper breakdown → | 2023 | 188 |
| 2 | 2019 | 88 | |
| 3 | 2017 | 86 | |
| 4 | 2019 | 78 | |
| 5 | 2020 | 71 | |
| 6 | 2018 | 70 | |
| 7 | 2013 | 49 | |
| 8 | 2023 | 43 | |
| 9 | 2016 | 36 | |
| 10 | 2022 | 29 | |
| 11 | 2023 | 27 | |
| 12 | 2023 | 26 | |
| 13 | 2022 | 20 | |
| 14 | 2024 | 18 | |
| 15 | 2018 | 15 | |
| 16 | 2021 | 8 | |
| 17 | 2023 | 4 | |
| 18 | Studies on the changes of protein secondary structure and carbohydrate contents in seedling-stage of Abrus cantoniensis Hance in drought stress based on FTIR and chemometrics. | 2015 | 1 |
| 19 | 2025 | 1 | |
| 20 | 2025 | 0 |
About Lan Fang
Lan Fang is a scholar working on Molecular Biology, Immunology, Surgery, Biomedical Engineering and Epidemiology, having authored 21 papers that have together received 858 indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (4 papers), interferon and immune responses (3 papers), Epigenetics and DNA Methylation (3 papers), Ubiquitin and proteasome pathways (2 papers), Cancer-related gene regulation (2 papers), IL-33, ST2, and ILC Pathways (2 papers), Advanced Nanomaterials in Catalysis (2 papers) and Inflammasome and immune disorders (2 papers). The work is most often cited by research in Immunology (333 citations), Cancer Research (92 citations), Oncology (161 citations), Molecular Biology (378 citations) and Biomaterials (46 citations). Lan Fang has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Linjun Weng, Yufeng Shi, Yue Liu, Qi Wu, Pengcheng Zhao, Yanjin Wang, Jin Zhang, Yanrong Yang, Ping Wang and Xin Ge. Their work appears in journals such as Advanced Science, Cancer Biology and Medicine, Developmental Cell, Signal Transduction and Targeted Therapy and Journal of Hematology & Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.